Heartflow, Inc. (HTFL) Stock Price & Analysis

Heartflow, Inc. (HTFL) rose 0.77% to USD 28.67 as of June 10, 2026 at 03:28 UTC, according to Nexqual real-time market data.

HTFL last closed at USD 28.45; the session ranged USD 27.98–29.66 on volume of 650,755 shares. Market capitalization is $2.47B, with a 52-week range of USD 20.13–41.22 (NMS). Source: Nexqual, June 10, 2026 at 03:28 UTC.

Key Statistics (as of June 10, 2026 at 03:28 UTC)

Technical Analysis (HTFL)

Nexqual's technical model rates HTFL "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:28 UTC.

Analyst Ratings (HTFL)

Wall Street analysts rate HTFL "Buy" based on 6 analysts, with a mean price target of USD 37 (range USD 35–40), per Nexqual as of June 10, 2026 at 03:28 UTC.

Earnings (HTFL)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 03:28 UTC.

Financials & Fundamentals (HTFL)

Source: Nexqual, June 10, 2026 at 03:28 UTC.

Financial Health Score (HTFL)

Nexqual rates Heartflow, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:28 UTC.

Ownership (HTFL)

Source: Nexqual, June 10, 2026 at 03:28 UTC.

Leadership (HTFL)

Heartflow, Inc. is led by John C.M. Farquhar (age 52), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:28 UTC.

Major Backers & Investors (HTFL)

Notable institutional backers of Heartflow, Inc. include Wellington Management, Bain Capital Life Sciences Investors, LLC, FMR, LLC, according to Nexqual as of June 10, 2026 at 03:28 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 03:28 UTC.

From Heartflow, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Data Security Our Heartflow Platform relies on industry-leading security controls, including encryption at rest and in transit, multi-factor and single-sign on authentication, granular authorization and a secure development lifecycle.
• Our clinical studies, including the PRECISE, NXT and PACIFIC trials, have consistently demonstrated that the Heartflow Platform is more accurate than traditional non-invasive tests and highly concordant to invasive testing, reduces unnecessary invasive testing, and enables physicians to optimize treatment and ultimately provide more efficient care.
• Our studies, including the PRECISE, NXT and PACIFIC trials, have consistently demonstrated that the Heartflow Platform is more accurate than traditional non-invasive tests and highly concordant to invasive testing, reduces unnecessary invasive testing, and enables physicians to optimize treatment and ultimately provide more efficient care.
• Intellectual Property Our success depends in part on our ability to obtain, maintain and defend our patent and other proprietary rights for the Heartflow Platform, the validity and enforceability of our patents, our ability to operate without infringing the valid and enforceable patents and proprietary rights of third parties and the continued confidentiality of our know-how and trade secrets.

Partnerships

• The study showed that Heartflow's Plaque Analysis results for total plaque volume, calcified plaque, and non-calcified plaque were strongly correlated with IVUS measurements, achieving 95% agreement with IVUS. • DECODE (2024): Our Company-sponsored DECODE study evaluated the impact of the Heartflow Plaque Analysis on clinical decision-making using data from 100 patients who underwent CCTA.
• The Heartflow Plaque Analysis has been validated against the reference standard of invasive IVUS and shown to have a 95% agreement with IVUS in quantifying total coronary plaque volume in our REVEALPLAQUE study.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:28 UTC. This page is informational and not investment advice.